ICH Q1B: A Forced-Degradation Screen Isn't the Confirmatory Study

Most CMC teams run a light-stress screen early in development — expose a batch to a bright cabinet for a few days, see what degrades, move on. That screen earns its keep as part of forced degradation under the stability program framework, where it helps validate stability-indicating methods and map degradation pathways. It is not the ICH Q1B confirmatory photostability study a registration dossier actually needs — and a reviewer can tell the difference on sight: a defined light source, a validated dose, and a dark control that a screening protocol rarely carries.

What the confirmatory study actually requires

Q1B covers both the drug substance and the drug product, normally in the immediate pack it will actually be marketed in, and it runs on the batches Q1A(R2)'s framework already anchors the stability program to. The sponsor picks a light source: Option 1 is any source engineered to approximate the D65/ID65 international daylight standard — an artificial daylight fluorescent lamp, xenon, or metal halide lamp, filtered below 320 nm if the source emits significant output there. Option 2 instead exposes the same sample to two separate lamps in sequence: a cool white fluorescent lamp and a near-UV fluorescent lamp spanning roughly 320 to 400 nm, with peak emission between 350 and 370 nm. Either option is acceptable on its own terms; what is not acceptable is treating the choice as cosmetic and skipping the exposure math that follows it.

Where the early screen falls short

The exposure numbers are not a suggestion. A sponsor has to confirm the dose the samples actually received — with a validated chemical actinometric system or calibrated radiometers and lux meters — because "we ran the light box for two weeks" is not evidence of 1.2 million lux hours. Most forced-degradation screens skip that validation entirely; they are built to find degradation pathways quickly, not to produce a defensible exposure record. They also typically skip the dark control: a protected, identically stored sample run in parallel that lets the sponsor distinguish light-driven degradation from ordinary thermal or hydrolytic change. Without it, a confirmatory-looking result proves nothing a reviewer can rely on. None of this is a knock on forced degradation itself — it is doing its real job, which is method validation and degradation-pathway mapping, not registration-grade photostability evidence.

A light-stress screen tells you whether the molecule can degrade under light. It does not tell a reviewer how much light it took, because nobody validated the dose. Why the confirmatory study can't be skipped

What the result decides

If the confirmatory study shows the drug substance or product changes materially under the defined exposure, that finding drives real decisions downstream: light-resistant primary packaging, "protect from light" or "store in original container" labeling under the firm's product labeling strategy, and sometimes a shortened in-use period once the container is opened. Q1B also allows a narrow shortcut — drug substance confirmatory testing can sometimes be waived if the product's own confirmatory data already demonstrates adequate photoprotection from its formulation and packaging. That argument only holds if it rests on real confirmatory data, not on a forced-degradation screen standing in for one. Sponsors who try to stretch screening data into that waiver are the ones who get the deficiency letter asking for the study they skipped.

ICH is not leaving Q1B untouched indefinitely. A consolidated ICH Q1 guideline — folding Q1A(R2), Q1B, Q1C, Q1D, Q1E, and Q5C into a single document — reached Step 2b of the ICH process on April 11, 2025, with a comment period that closed that July. As of this writing it has not reached Step 4 and no region has adopted it, so Q1B remains the standard a photostability package is actually reviewed against; treat the consolidation as directionally certain and its timeline as unsettled. Programs that keep the forced-degradation screen and the Q1B confirmatory study cleanly separated — in protocol, in data, and in the dossier narrative — are the ones that clear CMC review on the photostability section without a deficiency round. Our CMC regulatory strategy team builds that separation into the stability program from the first protocol, alongside the shelf-life work Q1E's extrapolation rules govern downstream.